Engineered biosynthesis of novel polyenes: a pimaricin derivative produced by targeted gene disruption in Streptomyces natalensis  by Mendes, Marta V et al.
Research Paper
Engineered biosynthesis of novel polyenes: a pimaricin derivative
produced by targeted gene disruption in Streptomyces natalensis
Marta V. Mendes a, Eliseo Recio a, Roberto Fouces a, Ruud Luiten b,
Juan F. Mart|¤n a;c, Jesu¤s F. Aparicio a;c; *
aInstitute of Biotechnology INBIOTEC, Parque Cient|¤¢co de Leo¤n, Avda. del Real, no. 1, 24006 Leo¤n, Spain
bDSM Anti-infectives, 624-0270, P.O. Box 1, 2600 MA Delft, The Netherlands
cArea of Microbiology, Faculty of Biology, University of Leo¤n, 24071 Leo¤n, Spain
Received 24 January 2001; revisions requested 20 March 2001; revisions received 26 March 2001; accepted 30 March 2001
First published online 8 May 2001
Abstract
Background: The post-polyketide synthase biosynthetic tailor-
ing of polyene macrolides usually involves oxidations catalysed by
cytochrome P450 monooxygenases (P450s). Although members
from this class of enzymes are common in macrolide biosynthetic
gene clusters, their specificities vary considerably toward the
substrates utilised and the positions of the hydroxyl functions
introduced. In addition, some of them may yield epoxide groups.
Therefore, the identification of novel macrolide monooxygenases
with activities toward alternative substrates, particularly epox-
idases, is a fundamental aspect of the growing field of
combinatorial biosynthesis. The specific alteration of these
activities should constitute a further source of novel analogues.
We investigated this possibility by directed inactivation of one of
the P450s belonging to the biosynthetic gene cluster of an
archetype polyene, pimaricin.
Results : A recombinant mutant of the pimaricin-producing
actinomycete Streptomyces natalensis produced a novel pimaricin
derivative, 4,5-deepoxypimaricin, as a major product. This
biologically active product resulted from the phage-mediated
targeted disruption of the gene pimD, which encodes the
cytochrome P450 epoxidase that converts deepoxypimaricin into
pimaricin. The 4,5-deepoxypimaricin has been identified by mass
spectrometry and nuclear magnetic resonance following high-
performance liquid chromatography purification.
Conclusions: We have demonstrated that PimD is the epoxidase
responsible for the conversion of 4,5-deepoxypimaricin to
pimaricin in S. natalensis. The metabolite accumulated by the
recombinant mutant, in which the epoxidase has been knocked
out, constitutes the first designer polyene obtained by targeted
manipulation of a polyene biosynthetic gene cluster. This novel
epoxidase could prove to be valuable for the introduction of epoxy
substituents into designer macrolides. ß 2001 Elsevier Science
Ltd. All rights reserved.
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1. Introduction
Pimaricin is a 26-member polyene macrolide antifungal
antibiotic [1] produced by Streptomyces natalensis ATCC
27448, which is widely used in the food industry in order
to prevent mould contamination of cheese and other non-
sterile foods (i.e. sausages, ham, etc.). Polyenes are planar
macrolide ring structures that interact with sterols with
high a⁄nity [1], and are therefore active against fungi,
but not bacteria. Their antifungal activity lies in their in-
teraction with membrane sterols, thus causing the altera-
tion of membrane structure and leading to the leakage of
cellular materials. Structurally, they are characterised by a
hydroxylated macrocycle containing one (amino)sugar,
but their distinct characteristic is the presence of a chro-
mophore formed by a system of three to seven conjugated
double bonds in the macrolactone ring. As other macro-
cyclic polyketides, pimaricin is synthesised by the action of
so-called type I modular polyketide synthases (PKSs) [2,3]
in a process resembling fatty acid biosynthesis [4^7], ex-
cept that the L-keto function introduced at each elonga-
tion step may undergo all, part or none of a reductive
cycle comprising L-ketoreduction and dehydration (other
macrolide synthase products also su¡er enoyl reduction
(for an example see [8]). These enzymes usually consist
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of several extremely large polypeptides in which di¡erent
modules (sets) of enzymatic activities catalyse each succes-
sive round of elongation [9,10], and so does pimaricin
synthase. Recently, we have characterised the organisation
of the pimaricin biosynthetic gene cluster and found 13
modules of a PKS distributed within ¢ve giant multien-
zyme proteins [3].
The structural variety in the polyene class of products
arises, as in other macrocyclic polyketides, from the choice
of monomers, the extent of L-ketoreduction and dehydra-
tion, and the stereochemistry of each chiral centre. Yet
further diversity is produced by functionalisation of the
polyketide chain by the action of glycosylases, methyl-
transferases and oxidative enzymes.
Such oxidative enzymes are usually cytochrome P450
monooxygenases which catalyse the site-speci¢c oxidation
of the precursors to many macrolide antibiotics. Examples
include erythromycin [11^13], tylosin [14], oleandomycin
[15], mycinamycin [16], narbomycin [17], epothilone
[18,19], methymycin [20], and rapamycin [21] among
others. However, although cytochrome P450s are common
in macrolide gene clusters, there are considerable varia-
tions in the substrates utilised, and the positions of the
resulting hydroxyl and/or epoxide substituents to such
compounds introduced by these enzymes. It is therefore
of great importance to identify and characterise additional
macrolide monooxygenases in order to target the increas-
ing number of novel polyketides obtained by combinato-
rial techniques [22^24]. Furthermore, the modi¢cation of
the genes encoding such oxidative enzymes could itself
lead to the generation of new polyketides.
Recently, the sequencing of the pimaricin gene cluster
revealed the presence of the pimD gene (Fig. 1), whose
deduced gene product bears striking sequence similarity
to authentic cytochrome P450 monooxygenases [3]. Here
we report the functional analysis of the pimD gene product
by phage-mediated gene disruption, and the ability of the
mutant thus obtained to synthesise a new pimaricin deriv-
ative, 4,5-deepoxypimaricin, as the sole fermentation prod-
uct.
2. Results
2.1. Disruption of the pimD gene
Since S. natalensis ATCC 27448 has so far proved ab-
solutely resistant to transformation by conventional pro-
cedures, we took advantage of the ability of phage KC515,
an attP-defective qC31 derivative [25], to infect S. nata-
lensis in order to introduce DNA into this strain. The
recombinant phage used for pimD disruption, q6D4,
was constructed as described in Section 5, and used to
infect S. natalensis in order to obtain lysogens. Because
Fig. 1. A portion of the pimaricin biosynthetic gene cluster which contains some non-PKS genes, including pimD (in red) and the second cytochrome
P450-encoding open reading frame (pimG) thought to be involved in pimaricin biosynthesis [3]. Pointed boxes indicate the direction of transcription.
Fragment a was used for gene disruption (see Fig. 2). Only NotI sites are shown. Fd; ferredoxin.
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phage KC515, and its derivative, lack attP, they can only
form lysogens by homologous recombination into the
chromosome (Fig. 2A).
Six lysogens of S. natalensis were obtained by selection
for thiostrepton resistance and tested for the lack of pi-
maricin production. One of these disrupted mutants was
randomly selected, and named S. natalensis 6D4. The
identity of the mutant was con¢rmed by Southern hybrid-
isation (Fig. 2B). Chromosomal DNAs isolated from
S. natalensis ATCC 27448 and mutant 6D4 and digested
with both BstXI and BglII were probed with the 667-bp
PvuII^SmaI fragment used to construct the KC515 deriv-
ative utilised for gene disruption (see Section 5). Hybrid-
ising bands of 1.9 kb and 1.5 kb were found for the wild
Fig. 2. Disruption of pimD. (A) Predicted restriction enzyme polymorphism caused by gene disruption. The BstXI^BglII restriction pattern before and
after disruption is shown. The probe is indicated by thick lines. The fragment used for gene disruption derives from fragment a in Fig. 1 (see text for
details). B, BamHI; Bx, BstXI; P, PstI ; Pv, PvuII; S, SmaI ; Z, BglII. (B) Southern hybridisation of the BstXI^BglII-digested chromosomal DNA of
the wild type (lane 1) and the mutant (lane 2).
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type as expected (Fig. 2B). However, in the disrupted mu-
tant, two new bands of 2.2 kb and more than 23 kb were
also detected (Fig. 2B), indicating that a single crossover
event had occurred with the phage derivative. The ob-
served hybridising bands corresponded exactly to those
expected according to the integration shown in Fig. 2.
2.2. A novel tetraene macrolide is formed in the
pimD-disrupted mutant
The broth produced by the mutant strain generated by
phage-mediated gene disruption was readily distinguish-
able from pimaricin synthesised by the wild type by spec-
Fig. 3. Comparison of spectral (A), and HPLC (B) analyses of butanol-extracted broths from S. natalensis wild type and 6D4 strains. (A) The peaks of
maximum absorption are indicated in both cases. Note that the typical chromophore absorption spectrum of a tetraene is present in the mutant strain.
(B) Arrows indicate the position of pimaricin or deepoxypimaricin, and the elution times of both compounds under the separation conditions used (see
text). Detection was carried out at O.D.304 nm. The UV^visible absorption spectra of both peaks are identical to the spectra shown in (A).
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trophotometric analysis of butanol-extracts of the culture
broths (see Section 5). Comparison of the UV^visible ab-
sorption spectrum of both S. natalensis ATCC 27448 and
6D4, revealed the typical absorption spectrum of the poly-
ene chromophore in both cases, but also a new absorption
peak in the mutant broth at 263 nm (Fig. 3A), suggesting
that a new compound was being produced by the recombi-
nant strain.
To rule out the possibility of S. natalensis 6D4 produc-
ing a mixture of pimaricin and the new product, the ex-
tracted broth was concentrated to dryness and subjected
to high-performance liquid chromatography (HPLC) and
thin layer chromatography (TLC). HPLC revealed a ma-
jor new peak with a slightly longer retention time (1.4 min
under the separation conditions assayed, see Section 5)
than the pimaricin present in the S. natalensis wild type
broth (Fig. 3B), whereas these two compounds were not
well resolved by TLC (not shown). Further spectral anal-
ysis of the compound present in the new HPLC peak
corroborated our previous observation, yielding an identi-
cal UV^visible absorption spectrum to the one in Fig. 3A.
The presence of the typical chromophore absorption spec-
trum of a tetraene with peaks at 319, 304, 291 and 281 nm,
together with the apparent absence of pimaricin in S. na-
talensis 6D4 broths strongly suggested that the new prod-
uct was a pimaricin-like molecule, and possibly a precur-
sor in its biosynthesis.
The existing correlation between the deduced domain
structure of the pimaricin synthase proteins [3] and the
pimaricinolide product indicates that in the ¢nal pimaricin
molecule there are two functions which do not derive from
the PKS, and could result from post-PKS oxidation cata-
lysed by P450 monooxygenases [3]. These include the ep-
oxy group at C4^C5, which should originate from a dou-
ble bond, and the exocyclic carboxyl function at C12 that
should derive from a methyl group (Fig. 4).
2.3. The novel compound corresponds to 4,5-
deepoxypimaricin
To distinguish between the two latter possibilities, the
compound present in the new peak was analysed by liquid
chromatography-mass spectroscopy (LC-MS) and LC-
MS-MS using atmospheric-pressure chemical-ionisation
(APCI) techniques, and compared with authentic pimari-
cin. The molecular mass of the new compound was thus
found to be 649, 16 masses lower than pimaricin (Fig. 5;
see Section 5 for the fragmentation pattern of pimaricin),
which was in agreement with the loss of one oxygen atom.
Furthermore, both pimaricin and the new component
showed a fragment loss of 163 (corresponding to the ami-
nosugar mycosamine), thus suggesting that no changes
had been introduced in the mycosamine moiety. More-
over, the masses of the principal peaks in the spectrum
of the new compound (Fig. 5) were in close agreement
with the values expected (i) for the molecular ion of pro-
tonated deepoxypimaricin (MH = 649.9), (ii) for a dehy-
drated deepoxypimaricin species (MH318 = 631.8), (iii)
for a mycosamine-minus species (MH3sugar = 487.0),
(iv) for the dehydrated mycosamine-minus deepoxypimar-
icin (MH3sugar318 = 469.0), (v) for an identical species
further dehydrated (MH3sugar32H2O = 451.1), and (vi)
for a dehydrated carboxyl-minus mycosamine-minus deep-
oxypimaricin (MH3sugar3183COOH = 425.1). How-
ever, a fragment loss of 44 from the unknown compound
suggested that it could still lose a carboxylic acid group.
In order to corroborate that the new component re-
tained the exocyclic carboxyl group of pimaricin, it was
dissolved in deuterium-labelled methanol. Such treatment
allows the replacement of all exchangeable H-atoms for
D-atoms. LC-MS-MS analysis of the new compound mea-
sured in a constant infusion mode yielded a m/z 659 (not
shown) that corresponds with a molecular mass of 657,
which indicated that the new compound still had eight
exchangeable H-atoms (like pimaricin), and therefore re-
tained the carboxyl group.
The spectrum of the novel compound was compared
with that of pimaricin using 2D nuclear magnetic reso-
nance (NMR) spectroscopic methods (COSY, TOCSY,
C^H correlation). The NMR data of the pimaricin deriv-
ative (Table 1) indicated that the signals of C4/H4 and C5/
H5 of the pimaricin molecule (epoxide function) were ab-
sent, although owing to overlap of double bonds were not
observed directly. Nevertheless, the signal of C6/H6
showed coupling to a double bond while the signals of
C7/H7 and C8/H8 remained as in the spectrum of pimar-
Fig. 4. Proposed conversion of 4,5-deepoxypimaricin into the pimaricin
molecule by PimD.
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icin. Therefore, the double bond of the new molecule
should be on C4^C5. Besides, the signal of H3 shifted
down¢eld due to the conjugation of C2NC3 with
C4NC5 double bonds.
Taken together, all the data identi¢ed the material
present in the peak as 4,5-deepoxypimaricin as a sole
product (Fig. 4), indicating that the gene product of
pimD is responsible for the epoxidation of the pimaricin-
olide ring at C4^C5, and that our previous deduction,
from the sequence analysis of pimS3, suggesting the intro-
duction of a double bond by PimS3 (a single-module en-
zyme of the pimaricin PKS corresponding to module 11)
was correct [3].
2.4. Biological activity and yield of 4,5-deepoxypimaricin
HPLC and LC-MS provided evidence for the accumu-
lation of 4,5-deepoxypimaricin as the sole PKS product in
S. natalensis 6D4 culture broths. In order to characterise
the biological activity of the new product; we initially
compared bioassays performed with butanol-extracted cul-
ture broths from early stationary phase-grown S. natalen-
sis 6D4 cells with those of the parent strain. In every case
analysed we found a consistent halo of growth inhibition
of the Candida utilis CECT 1061 cells used as test organ-
ism (not shown), indicating that 4,5-deepoxypimaricin re-
tains antibiotic activity.
Under the growth conditions used (see Section 5) the
yields of pimaricin and 4,5-deepoxypimaricin in YEME
medium without sucrose were very similar, in the range
220^310 Wg of product per mg of dry cells (about 0.7 g/l).
After puri¢cation of the product by HPLC, the antibiotic
activity of deepoxypimaricin was found to be substantially
lower than that of pimaricin, showing a minimal inhibi-
tory concentration of 70 Wg/ml, 10 times higher than the
one for pimaricin.
Fig. 5. MS identi¢cation of deepoxypimaricin produced by S. natalensis 6D4. (A) Spectrum showing the molecular ion MH (649.9) of this new com-
pound and dehydration and mycosamine-minus species (see text for a detailed description of the signals). (B) Spectrum of pimaricin, showing the molec-
ular ion MH (666.1) of the complete molecule, and its fragmentation pattern.
Table 1
Selection of 1H and 13C NMR data for 4,5-deepoxypimaricin and
pimaricina
Positionb 1H N (ppm) 13C N (ppm)
2 5.58 (6.29) 121.9 (125.0)
3 6.92 (6.55) 146.3 (144.9)
4 6.07c (3.32) 132.2 (54.5)
5 6.07c (2.89) 134.9 (59.0)
6 2.16 (2.10) 43.7 (40.1)
7 4.03 (4.26) 69.4 (66.6)
1P 4.47 (4.63) 99.7 (98.1)
Only the chemical shifts of the most relevant signals are listed. The sig-
nal of C1P is included to show that the sugar moiety is still present in
the mutant.
aData in parentheses are chemical shifts for equivalent positions in pi-
maricin.
bPositions are labelled according to their number in the polyketide
backbone (Fig. 4).
cOverlapping signals.
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3. Discussion
The widespread clustering of the biosynthetic genes
needed to make a particular secondary metabolite [26]
has been a tremendous aid in the isolation of genes in-
volved in polyketide biosynthesis [7], and also a good in-
dication for the assignment of functions to genes whose
role in the biosynthesis would not be otherwise obvious.
Such reasoning was used to propose a function for the
pimD gene product on the tailoring of the pimaricinolide
aglycone [3] ; however, the sole presence of a gene within a
biosynthetic gene cluster does not justify its involvement in
biosynthesis. The existence of genes within a secondary
metabolite biosynthetic gene cluster, which are not essen-
tial for its biosynthesis, has been reported. Thus, in the
mithramycin gene cluster it has been shown that mtmOI
and mtmOIII (genes encoding oxygenases) are not essen-
tial for mithramycin biosynthesis [27], and in the erythro-
mycin gene cluster it has been demonstrated that eryBI
(encoding a L-glucosidase) is also not essential for eryth-
romycin biosynthesis [28]. In this paper we describe the
¢rst polyene derivative obtained by targeted manipulation
of a polyene biosynthetic gene cluster. We have used
phage-mediated gene disruption to produce a S. natalensis
mutant inactivated in the pimD gene. The strain so gen-
erated produced a pimaricin derivative as a shunt metab-
olite, thus establishing the link of pimD with pimaricin
biosynthesis.
Sequencing analysis of the pimaricin PKS genes
prompted us to predict, based on the general colinearity
and processivity of type I PKSs [9,10,29,30], that the ep-
oxide of pimaricin, at C4^C5, could originate from a dou-
ble bond introduced by PimS3 during polyketide chain
elongation by the pimaricin PKS. PimS3 contains a single
module for chain extension (module 11) and has L-ketoac-
yl-ACP synthase, acyltransferase, L-ketoacyl-ACP reduc-
tase, L-hydroxyacyl-thioester dehydratase and acyl carrier
protein functional domains. Therefore, such a module
would generate a trans double bond between carbons
4 and 5 of the pimaricinolide product of the PKS (Fig. 4)
[3]. Post-PKS epoxidation was hence expected to occur on
such double bond to yield the epoxy functionality of pi-
maricin. On the basis of sequence comparison with au-
thentic cytochrome P450 monooxygenases, PimD was pro-
posed as a possible candidate to catalyse such epoxidation.
However there is a second hydroxylase (PimG) in the pi-
maricin biosynthetic cluster that could also ful¢l such role
[3].
As pimD is transcribed on a monocistronic RNA (Fig.
1), expression of the remaining genes of the pimaricin
biosynthetic gene cluster should not be a¡ected by any
polar e¡ect of its disruption. The production of 4,5-deep-
oxypimaricin by S. natalensis 6D4 (Fig. 4), as veri¢ed by
LC-MS and NMR, in which pimD has been disrupted,
corroborated our previous assumptions about pimD tran-
scription and polyketide chain assembly, and demon-
strated that PimD is in fact the enzyme responsible for
the formation of the epoxide functionality in the ¢nal
pimaricin molecule.
A preliminary characterisation of the biological activity
of the new product, 4,5-deepoxypimaricin, indicates lower
antibiotic activity than pimaricin. However, other param-
eters important for the applicability of this new product
such as host-range, toxicity and acid or alkali stability will
establish the future economical importance of the ¢nding
presented here.
The accumulation of 4,5-deepoxypimaricin in the mu-
tant as a major product also indicates that the reaction
catalysed by PimD does not a¡ect the modi¢cations intro-
duced by other tailoring enzymes on their pimaricinolide
substrate. Therefore, either the epoxidation reaction is the
last step in the biosynthetic pathway as has been suggested
in oleandomycin biosynthesis [31], or the modifying en-
zymes for the latter steps of the pathway do not discrim-
inate against substrates with variations at C4^C5. This
lack of substrate discrimination in polyketide tailoring en-
zymes is not unprecedented. Inactivation of the C6 hy-
droxylase in the erythromycin A biosynthetic pathway
by plasmid-mediated gene disruption of eryF results in
the production of 6-deoxyerythromycin A [12], thus imply-
ing that the remaining tailoring enzymes of the erythro-
mycin pathway can utilise 6-deoxyerythronolide B as sub-
strate. Further characterisation of the pimaricin
biosynthetic route will permit the validation of one of
these hypotheses.
With the development of combinatorial biosynthesis
[32], a growing number of novel macrolide analogues
have already been produced by genetic engineering macro-
lide gene clusters [10,12,33^45]. In many cases, however,
the modi¢ed compounds lack post-PKS hydroxylations,
possibly owing to the apparent strict substrate speci¢cities
of these oxidising enzymes. The identi¢cation of novel
macrolide monooxygenases with activities toward alterna-
tive substrates is, therefore, a crucial aspect for the oxida-
tive tailoring of novel polyketides, and should facilitate the
search for new bioactive macrolide compounds. This novel
epoxidase could thus prove valuable for the introduction
of epoxy substituents into designer macrolides in the fu-
ture.
4. Signi¢cance
Polyenes represent a major class of antifungal agents
characterised by the presence of a series of conjugated
double bonds in their planar hydroxylated macrolide
ring structure. Despite their general interest, very little
was known about their biosynthetic routes, and only the
recent description of the biosynthetic gene clusters for pi-
maricin and nystatin has provided some clues for the ra-
tional design of polyene derivatives with improved proper-
ties. This report addresses the functional disruption of the
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gene pimD, which encodes an authentic cytochrome P450
monooxygenase, as a mean to generate a derivative of the
polyene pimaricin. The 4,5-deepoxypimaricin accumulated
by the recombinant mutant of the pimaricin-producing
actinomycete S. natalensis shows that PimD is the enzyme
responsible for the introduction of the peculiar epoxy moi-
ety in the pimaricin macrolactone structure. This novel
epoxidase could prove valuable for the introduction of
epoxy substituents into designer macrolides in the future.
The work represents the ¢rst description of a polyene ana-
logue obtained by targeted manipulation of a polyene bio-
synthetic gene cluster.
5. Materials and methods
5.1. Bacterial strains, cloning vectors and cultivation
S. natalensis ATCC 27448 was routinely grown in YEME me-
dium [46] without sucrose. Sporulation was achieved in TBO
medium (2% (w/v) tomato paste, 2% (w/v) oats £akes, 2.5% (w/
v) agar) at 30‡C. For pimaricin production, the strain was grown
in YEME without sucrose. The same media were supplemented
with thiostrepton when used for S. natalensis 6D4 growth and/or
metabolite production. Escherichia coli strain XL1-Blue MR
(Stratagene) was used as a host for plasmid subcloning in plas-
mids pBluescript (Stratagene), pUC18 and pUC19. C. utilis (syn.
Pichia jadinii) CECT 1061 was used for bioassay experiments.
Phage KC515 (c attP: :tsr: :vph), a qC31-derived phage [25],
was used for gene disruption experiments. Streptomyces lividans
JII 1326 [47] served as a host for phage propagation and trans-
fection. Infection with q6D4 (the KC515 recombinant derivative
used for disruption) was carried out on R5 medium [46]. Stan-
dard conditions for culture of Streptomyces species and isolation
of phages were as described by Kieser et al. [46].
5.2. Genetic procedures
Standard genetic techniques with E. coli and in vitro DNA
manipulations were as described by Sambrook et al. [48]. Re-
combinant DNA techniques in Streptomyces species and isolation
of Streptomyces total and phage DNA were performed as previ-
ously described [46]. Southern hybridisation was carried out with
probes labelled with digoxigenin by using the DIG DNA labelling
kit (Roche Molecular Biochemicals).
5.3. Construction of a pimD mutant
The pimD gene was disrupted by KC515 phage-mediated single
crossover integration as follows. A 667-bp PvuII^SmaI fragment
internal to the pimD gene was cloned into a HincII-cut pUC18
vector to yield pMVM1. This plasmid was then used as a source
of DNA for subcloning into KC515 [25]. A 690-bp BamHI^PstI
fragment (both sites belong to the polylinker of pUC) was ligated
into the BamHI^PstI sites of KC515. Transfection of S. lividans
protoplasts [46] resulted in a number of phage plaques that were
screened by Southern hybridisation for the presence of pimD-
derived sequences. One of the recombinants, q6D4, was selected
and used to infect S. natalensis thus allowing the selection for
lysogen formation. Lysogens were selected by thiostrepton resis-
tance on R5 medium, and con¢rmed by genomic Southern hy-
bridisation.
5.4. Spectral analysis, bioassay, and metabolite concentration
determination
To assay pimaricin in culture broths, 0.5 ml of culture was
extracted twice with 4 ml of butanol, and the organic phase
was diluted in water-saturated butanol to bring the O.D. at 319
nm in the range of 0.1 to 0.4 absorbance units. Control solutions
of pure pimaricin (DSM, Delft, The Netherlands) were used as
control. To con¢rm the identity of pimaricin, an UV^visible ab-
sorption spectrum (absorption peaks at 319, 304, 291 and 281
nm) was routinely determined in a Hitachi U-2001 spectropho-
tometer. The fungicidal activity of pimaricin or 4,5-deepoxypi-
maricin was tested by bioassay using C. utilis CECT 1061 as
test organism. Quantitative determination of pimaricin, or its
derivative, was performed with a Shimadzu VP HPLC with a
diode array ultraviolet detector set at 304 nm, ¢tted with a
W-Bondapack RP-C18 column (10 Wm; 3.9U300 mm). Elution
was with a gradient (1.5 ml/min) of 100% methanol (methanol
concentration: 50% 0^3 min, up to 90% 3^12 min, 90% 12^20
min, down to 50% 20^25 min, 50% 25^30 min). Retention time
for pimaricin was 8.6 min. TLC was performed on silica 60 F254
plates (Merck), and elution was carried out with water:butanol:
acetic acid (4:5:1).
5.5. Structural elucidation of 4,5-deepoxypimaricin
Fermentation broths were harvested by centrifugation after
2 days of growth at 300 rpm and 30‡C, and the supernatant
extracted with eight volumes of butanol. This was repeated
once, and the solvent was removed from the combined extracts
in vacuo to yield a dry powder. Two gram of the residue thus
obtained was dissolved in methanol (10 ml) and centrifuged to
remove particulate matter before the supernatant (50 Wl) was
analysed using LC-MS and LC-MS-MS.
The fragmentation pattern for authentic pimaricin (Fig. 5) was
as follows: (M)H m/z = 666.1; (M3H20)H m/z = 647.9;
(M3mycosamine ring)H m/z = 502.9; (M3mycosamine ring-
H2O)H m/z = 484.9; (M3mycosamine ring32H2O)H m/
z = 467.1; (M3mycosamine ring33H2O)H m/z = 449.1;
(M3mycosamine ring3H2O3COOH)H m/z = 441.1.
To replace all exchangeable H-atoms of the pimaricin deriva-
tive for D-atoms, the dry pellet (see above) was washed twice
with deuterium-labelled methanol, and redissolved in the same
solvent (2 ml). This solution was then centrifuged, and the clear
supernatant (50 Wl) used for analysis.
All LC-MS and LC-MS-MS experiments were carried out us-
ing a LCQ apparatus (ThermoQuest, Breda, The Netherlands). A
pimaricin solution (5 mg/ml methanol) was used for tuning. Anal-
yses were run using an APCI interface and positive ionisation
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mode. Chromatography and column characteristics were as indi-
cated above. NMR spectra were recorded using a Bruker DRX-
600 spectrometer equipped with a 5-mm inverse triple resonance
probe with self-shielded gradients. Samples were dissolved in
CD3OD before injection. Assignment was achieved by means of
standard 2D techniques (COSY, TOCSY, and HSQC), and by
comparison with the spectrum of pimaricin.
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